Core Insights - Kiora Pharmaceuticals has appointed Lisa Walters-Hoffert as an independent member of its Board of Directors, bringing extensive experience in biotech and investment banking [16][7] - The company is focused on advancing its pipeline of investigational treatments for retinal diseases, specifically KIO-301 and KIO-104 [2][13] - Ken Gayron will step down from the Board, marking a significant transition as Kiora continues its strategic growth [16][11] Company Overview - Kiora Pharmaceuticals is a clinical-stage biotechnology company dedicated to developing and commercializing products for orphan retinal diseases [13] - KIO-301 is aimed at treating retinitis pigmentosa, choroideremia, and Stargardt disease, while KIO-104 targets posterior non-infectious uveitis [13] - The company has reported promising data from KIO-301 and established a strategic partnership for co-development and commercialization [11] Leadership and Governance - Lisa Walters-Hoffert will serve as chair of the audit committee and a member of the compensation committee [16] - She has over 25 years of experience in investment banking, particularly with small-cap public companies in life sciences and technology [7] - Walters-Hoffert has held significant roles in various financial institutions, including Roth Capital Partners and Citicorp Securities [7] Financial Position - Kiora has capitalized the company with an expected runway for at least the next two years, allowing for continued investment in its therapies [11] - The company is positioned to leverage its financial resources to advance the development of KIO-104 [11]
Biotech Executive Lisa Walters-Hoffert Joins Kiora Pharmaceuticals' Board of Directors